+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

O

Actively Recruiting

Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.

All AgesAll Genders
29 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of BR005-036C tablets compared to placebo in adults experiencing acute migraine attacks, including those with or without aura. This phase IIIII, multicenter, randomized, double-blind study aims to better understand how well BR005-036C works to relieve migraine symptoms and how it compares to placebo treatment. Participants are randomly assigned to take one of two doses of BR005-036C oral tablets or a matching placebo tablet. The study assesses the medications effects shortly after dosing, focusing on relief from pain and bothersome symptoms within two hours. The trial includes a treatment period with close monitoring for up to nine days after taking the study drug. During the study, participants will be monitored for migraine pain relief, freedom from symptoms, use of rescue medications, and functional ability after dosing. Researchers will track adverse events and other safety measures throughout the treatment period. The primary outcomes focus on pain freedom and symptom relief two hours after dosing, with additional assessments up to 48 hours. Participants involvement includes medication dosing and follow-up visits to assess their response and safety.

Age: 18Years +All GendersPhase 2Phase 3
83 locations
I

Actively Recruiting

The trial focuses on hospitalized children aged 0 to 18 years who require gastric tube placement, aiming to improve practices in pediatric enteral nutrition. Researchers are evaluating evidence-based methods to enhance safety and effectiveness in tube placement by addressing gaps between current practices and the latest guidelines. This quality improvement project seeks to update healthcare professionals knowledge and standardize procedures to improve pediatric care quality. The study involves establishing an enteral nutrition management team that will lead a 3-month quality improvement initiative. During this time, pediatric nurses will receive regular training through lectures, group discussions, demonstrations, and simulations focused on gastric tube placement and maintenance. The project will observe changes in compliance with protocols and nursing knowledge as the new practices are implemented. Participants will be monitored through assessments of protocol adherence and knowledge levels before and after the intervention. Data collected will include compliance rates with gastric tube placement protocols and the personal knowledge of nursing staff. The study aims to ensure safer and more effective tube placement, with evaluations conducted throughout the 3-month implementation period and ongoing support for nurses.

Age: 0 - 18YearsAll GendersPhase Not Applicable
22 locations
S

Actively Recruiting

Radiation-induced lung injury RILI is a common complication after thoracic radiotherapy, occurring in about 31.4% of patients. This condition, sometimes combined with immune-checkpoint inhibitor-related pneumonitis CIP, can disrupt cancer treatment and negatively affect patient outcomes. Both RILI and CIP share similar symptoms like fever, dry cough, and chest pain, and diagnosis involves symptom assessment and imaging such as computed tomography CT. This trial aims to find the best dose and evaluate the safety and effectiveness of pirfenidone capsules for treating RILI with or without CIP, addressing a critical need for better therapies. The study has two phases Phase II focuses on finding the optimal dose of pirfenidone, testing low-dose 400 mg three times daily, high-dose 600 mg three times daily, and placebo groups over 168 days of treatment and observation, followed by safety and survival follow-up. Phase III will confirm the chosen doses effects compared to placebo with a similar schedule and includes a long-term extension phase with survival assessments every three months. Participants will receive oral pirfenidone capsules or placebo with meals during the treatment period. Participants will undergo regular assessments including lung function tests like diffusing capacity of the lung for carbon monoxide DLCO, forced vital capacity FVC, and forced expiratory volume in one second FEV1. Other evaluations include symptom scores, CT imaging, blood tests, and monitoring for adverse events. The primary outcome is the change in lung diffusion capacity at 24 weeks. Safety follow-up occurs for about a month after treatment, and long-term monitoring continues in the extension phase. The total study participation spans from screening through treatment, safety follow-up, and extended survival tracking.

Age: 18Years - 75YearsAll GendersPhase 2Phase 3
36 locations
E

Actively Recruiting

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of TQC2731 injection in adults with severe asthma that is not adequately controlled. The study aims to compare TQC2731 with a placebo to better understand its impact on asthma exacerbations and other clinical outcomes in this population. Participants are randomly assigned in a 11 ratio to receive either TQC2731 injection or placebo via subcutaneous injection every 4 weeks. Treatment cycles last 4 weeks each, with study drug administration continuing from Day 0 up to Week 48. The trial includes two groups one receiving the active drug and the other receiving placebo, both with the same dosing schedule. During the study, participants will be monitored for asthma exacerbations, lung function through forced expiratory volume in 1 second FEV1, asthma control questionnaires, quality of life assessments, symptom diaries, and biomarker changes such as blood eosinophils and immunoglobulin E levels. Safety assessments include monitoring for anti-drug antibodies and neutralizing antibodies. The primary outcome is the annualized incidence of asthma exacerbations from the first day of dosing through 52 weeks. Secondary outcomes and safety follow-up extend up to Week 64.

Age: 18Years - 75YearsAll GendersPhase 3
101 locations